Rodríguez-Noriega E, Morfin-Otero R, Esparza-Ahumada S
Instituto de Patología Infecciosa y Experimental Dr. Francisco Ruíz Sánchez, Universidad de Guadalajara, Jalisco, México.
Drugs. 1993;45 Suppl 3:42-5. doi: 10.2165/00003495-199300453-00009.
The size of the antibiotic market in developing countries is double that seen in developed countries. There are some valid reasons for this difference, one of which is the higher frequency of diverse infections in the developing world. However, other factors are involved: for example, antibiotics are available without prescription, package insert information is poor, and there is no national antibiotic usage programme, all of which encourage inappropriate antibacterial use. When an antibiotic becomes widely prescribed by physicians, this is interpreted by the general public as meaning that the antibiotic is useful for all types of infections and the process of automedication begins. The newer quinolones, other new antibiotics, and indeed all antimicrobials should be available only by prescription. A package insert that includes all pertinent information should be provided, and each country should implement a comprehensive national antibiotic usage programme. Only through these measures will bacterial resistance be controlled and the effectiveness of each antibiotic class be maintained.
发展中国家抗生素市场的规模是发达国家的两倍。造成这种差异有一些合理原因,其中之一是发展中世界各类感染的发生频率较高。然而,还涉及其他因素:例如,抗生素无需处方即可获得,药品说明书信息不完善,且没有国家抗生素使用计划,所有这些都助长了抗菌药物的不当使用。当一种抗生素被医生广泛开出处方时,普通民众会将此理解为该抗生素对所有类型的感染都有用,自我药疗过程就此开始。新型喹诺酮类药物、其他新型抗生素以及实际上所有抗菌药物都应仅凭处方供应。应提供包含所有相关信息的药品说明书,每个国家都应实施全面的国家抗生素使用计划。只有通过这些措施,才能控制细菌耐药性并维持各类抗生素的有效性。